Here are three things to know about the deal.
1.The companies will collaborate to develop Conatus’ drug emricasan, which is an experimental first-in-class oral treatment for patients with non-alcoholic steatohepatitis with advanced fibrosis and cirrhosis.
2. San Diego-based Conatus will receive $50 million upfront and also be eligible to receive significant payments for various developmental, regulatory and commercial milestones.
3. Conatus will conduct multiple Phase IIb clinical trials of the drug and, if successful, Novartis would then conduct Phase III studies of the drug. The Swiss drugmaker would also develop the drug in combination with its own experimental chronic liver disease medication, reports Reuters.
More articles on supply chain:
Supply chain tip of the week: How to put your supply chain on a ‘diet’
Survey: 19M Americans have purchased cheaper drugs across US borders
Opinion: 4 reasons drug prices will continue to rise in 2017
